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multiple testing in statistical analysis was done using the 
Benjamini-Hochberg method. 
 
Results: With a median follow up of 34 months, the 3-year 
LC, PFS and OS (with 95% confidence intervals) were 64% (53% 
- 75%), 51% (39% - 62%) and 77% (67% - 87%), respectively. No 
image features were significantly correlated with LC or PFS 
and adding image features to the clinical variables did not 
improve the performance of the Cox model in the bCV 
setting, as seen in Table 1 where the C-index is highlighted in 
bold if adding image features improved performance.  
 
 
 
MTV was the image feature most closely related to OS and for 
OS the addition of image features did improve the predictive 
performance of the Cox model. Figure 1 shows the effect of 
dividing the patient population based on the statistically 
most important variables, where it is clear that Karnofsky 
performance score and MTV affect the OS. 
 
 
Conclusion 
Adding image features to complement clinical parameters 
was seen to improve the prognostic value for OS. Although no 
significant image features were found related to LC and PFS, 
we found that a smaller MTV was predictive of improved OS. 
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Purpose or Objective: Among cancers of head and neck, 
hypopharyngeal cancers tend to have an aggressive clinical 
course. Chemoradiation has become the standard of care for 
patients who are candidates for an organ preservation 
strategy. IMRT planning has incorporated a simultaneous 
integrated boost (SIB-IMRT) in order to efficiently develop 
comprehensive radiation therapy plans and also potentially 
lessen treatment time and toxicity. Outcomes and toxicites 
of patients with hypopharyngeal cancers treated in a single 
institute with standard IMRT and SIB-IMRT schedules were 
analyzed retrospectively. 
 
Material and Methods: A total of 86 patients with 
hypopharyngeal squamous cell carcinomas were treated 
between September 2010 and December 2014. Among 44 
patients who were treated using SIB-IMRT, 8 received 
neoadjuvant chemotherapy (NACT) and 42 received 
concurrent chemotherapy. Among 42 patients who were 
treated using IMRT with conventional fractionation (IMRT),16 
received NACT and 40 received concurrent chemotherapy. 
The dose for SIB-IMRT group was 65 Gy in 30 fractions to gross 
and high risk disease and 54 Gy in 30 fractions to low-risk 
nodes. The dose in IMRT group was 66-70 Gy to gross disease, 
60 Gy to high risk nodes and 50 Gy to low risk nodes in 1.8-2 
Gy per fraction. 
 
Results: At a median follow-up of 16.5 months (6-56 months) 
the median OS of entire cohort was 38.9 months. The mean 
OS was 37.5 months and 38.3 months (p=0.91) for SIB-IMRT 
and IMRT respectively. The mean treatment duration for SIB-
IMRT and IMRT groups was 42 days (range: 38-51 days) and 
48.4 days (range: 45-73 days) respectively. 98 % in SIB-IMRT 
and 93 % patients in IMRT group completed the intended 
treatment. Complete response was noted in 89 % and 93 % in 
SIB-IMRT and IMRT groups respectively. The estimated 1 year, 
2 year LR control and 2-year DFS were 81%, 66.6%, 67.4% in 
SIB-IMRT and 84%, 74%, 62% (p<0.81) in IMRT groups 
respectively.Grade 3 mucositis occurred in 10 (23%) and 12 
(28%), grade 3 dermatitis in 9 (20.5%) and 12 (28%) of SIB-
IMRT and IMRT patients respectively. Grade 2 xerostomia 
occurred in 11 patients (27%) and 15 patients (34%) in IMRT 
and SIB-IMRT groups. Grade 3 soft-tissue fibrosis and 
esophageal stricture rates were 2 (4.7 %) and 5 (11.4%) in SIB-
IMRT and IMRT groups. 
 
 
 
Conclusion: Clinical outcomes, acute and late toxicities of 
chemo-radiation with SIB-IMRT were comparable with IMRT. 
Overall treatment duration was reduced and more patients 
completed intended treatment in SIB-IMRT group with 
relatively lesser acute toxicities. 
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Purpose or Objective: Radiation Therapy Oncology Group 
(RTOG) guidelines recommend brachial plexus dose 
constraints ranging from 60-66Gy in 2Gy per fraction (BED = 
120-132Gy2). However there remains limited data on brachial 
plexus (BR.P) toxicity and furthermore the dose limits are 
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often below those required to control gross disease. This 
study was done to explore the incidence of brachial plexus 
injury following radical (chemo) radiotherapy in the IMRT 
era. 
 
Material and Methods: Patients with head and neck cancer 
that had completed IMRT to unilateral or bilateral neck with 
a minimum of 2 years of follow up were identified from a 
prospective database. All patients underwent clinical review 
as per local protocol which was commonly 6 weekly. The 
brachial plexus was contoured based on RTOG Atlas. 
Maximum dose (Dmax) to brachial plexus was recorded from 
DVH. All doses were converted to BED using an α/β ratio of 2. 
A review of electronic records was performed to determine 
brachial plexus toxicity using CTCAE v 3.0. 
 
Results: Seventy five patients met the inclusion criteria. Ten 
patients were excluded due to insufficient dose metric data. 
Of sixty five patients analysed, 37 patients were treated for 
oropharyngeal, 2 for nasopharyngeal, 6 for Hypopharyngeal, 9 
for Larynx, 8 for oral cavity cancers and 3 for unknown 
primary site. Forty five patients had concurrent 
chemotherapy (31 cisplatin, 8 carboplatin and 6 cetuximab). 
Brachial plexus dosimetry is given in table 1. Maximum point 
BED to brachial plexus reached 149.5Gy2 (41.3-149.5). There 
were no reported symptoms of brachial plexopathy during 
this period. 
 
Conclusion: It is often necessary to accept higher than 
conventional maximum point doses to the brachial plexus to 
ensure adequate PTV coverage for head and neck cancers. 
Although longer term follow-up is required ideally with nerve 
conduction studies, such an approach of exceeding 
conventional limits appears to be acceptable. Further data 
will be presented for patients exceeding conventional 
constraints. 
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Purpose or Objective: To present long-term results on 
disease control and late toxicity in both primary and post-
operative re-irradiation in the head and neck region. 
 
Material and Methods: Retrospective single center analysis 
of 137 patients re-irradiated between 1986 and 2013 for a 
recurrent or second primary malignancy. Inclusion criteria 
were a prescribed dose of at least 45 Gy in first treatment 
and re-treatment and histological proof of disease. Exclusion 
criteria were age under 18 years, the presence of metastatic 
disease and the use of brachytherapy. Endpoints were 
locoregional control (LRC), disease-free survival (DFS), event-
free survival (EFS), overall survival (OS) and grade ≥3 late 
complications according to EORTC/RTOG criteria. EFS 
includes both disease recurrence and late treatment 
complication as an event.  
As 3D-dose distribution data was not available for all 
patients, a descriptive approach was used to determine the 
highest cumulative dose in radiation overlap and organs at 
risk (spinal cord, larynx, mandible and optical nerve).  
 
Results: Patient and tumor characteristics are presented in 
table 1. 
 
  
The median re-irradiation and cumulative radiation dose 
were 60 Gy (range 45-70) and 126 Gy (range 68-138) 
respectively. Two- and five-year LRC were 52% and 40%, two- 
and five-year DFS were 38% and 28% respectively (figure 1). 
There were 17 observations of serious late toxicity in 11 
patients (actuarial 26% at 5 years): chondronecrosis (n=1), 
osteoradionecrosis (n=8), soft tissue necrosis (n=3), arterial 
blowout (n=3), and stricture/fistula (n=2). Three cases of 
treatment-related death were reported. Multivariate analysis 
revealed IMRT as re-irradiation technique to be protective of 
late complications (HR, 0.10; 95% CI, 0.01-0.96). The five-
year actuarial EFS was 18%.  
 
 
One-hundred-and-seven patients (78%) were re-irradiated 
post-operatively and had a better LRC in comparison to re-
irradiation alone (actuarial 5-yr 46% vs 16%, p<0.05). Of 
patients re-irradiated alone without surgery, patients re-
irradiated for a second primary tumor had significant better 
LRC-rates in comparison with patients re-irradiated for 
